Lilly/BI 'biosimilar Lantus' filed in Europe
This article was originally published in Scrip
Eli Lilly and and Boehringer Ingelheim have had their marketing authorization application (MAA) for the biosimilar LY2963016, a basal (long-acting) insulin analog for the treatment of type 1 and type 2 diabetes, accepted for review by the European Medicines Agency. LY2963016 is a new insulin glargine product and was filed through the EMA's biosimilar pathway.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.